Ann: Significant Neuroprotection in NYR Preclinical Brain Injury, page-132

Firstly what demand for its product? It’s a biotech and a drug development program. Secondly 10 million in funding takes them to phase 2 and a further 5-10 million in non dilutive funding from the US defence force allowing them to complete phase 2 FDA progress

Your a special character Smiteoff they are fullly funded to a JV after phase 2 as the CEO highlighted in his interviews. A drug like this on JV as revolutionary as it is, is worth north of a billion dollars because the target market is so large

Im happy with my average below the 7.5 cents the directors paid and will let the news flow come in one at a time over the next couple of weeks and throughout next quarter and the quarter after and the quarter after that. I’m an investor not a trader like yourself